Evidence map›Paper›PMID 29906493›Full record

ArticleToxicology and applied pharmacology2018

The tamoxifen derivative ridaifen-B is a high affinity selective CB

Lirit N Franks, Benjamin M Ford, Toshifumi Fujiwara, Haibo Zhao, Paul L Prather

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxicology and applied pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Endocannabinoid System and Metabolism: The Influences of Sex.International journal of molecular sciences · 2024
    Review
  3. Article
  4. Molecules (Basel, Switzerland) · 2022
    Article
  5. Review
  6. Article
  7. Sex differences and the endocannabinoid system in pain.Pharmacology, biochemistry, and behavior · 2021
    Review
  8. Future Aspects for Cannabinoids in Breast Cancer Therapy.International journal of molecular sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Lirit N FranksDepartment of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Benjamin M FordDepartment of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Toshifumi FujiwaraDepartment of Internal Medicine, Endocrinology Division, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Haibo ZhaoDepartment of Internal Medicine, Endocrinology Division, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA. Electronic address: hzhao@uams.edu.
Paul L PratherDepartment of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA. Electronic address: pratherpaull@uams.edu.
University of Arkansas for Medical Sciences · US

Funding

Synthetic Cannabinoid Toxicity: Role of BiotransformationR01DA039143 · NIDA · UNIV OF ARKANSAS FOR MED SCIS · PI PRATHER, PAUL L · 2016 to 2020
$2.9M
Mechanisms of Cytoskeletal and Lysosomal Protein Regulation in OsteoclastsR01AR062012 · NIAMS · UNIV OF ARKANSAS FOR MED SCIS · PI ZHAO, HAIBO · 2011 to 2015
$1.6M
Structural and functional analyses of Rab7 binding to Plekhm1R21AR068509 · NIAMS · UNIV OF ARKANSAS FOR MED SCIS · PI VARUGHESE, KOTTAYIL I, ZHAO, HAIBO · 2016 to 2017
$361k
NIAMS NIH HHS R01 AR062012NIAMS NIH HHS R21 AR068509NIDA NIH HHS R01 DA039143
6 · The paper itself

Abstract

Selective estrogen receptor modulators (SERMs) target estrogen receptors (ERs) to treat breast cancer and osteoporosis. Several SERMs exhibit anti-cancer activity not related to ERs. To discover novel anti-cancer drugs acting via ER-independent mechanisms, derivatives of the SERM tamoxifen, known as the "ridaifen" compounds, have been developed that exhibit reduced or no ER affinity, while maintaining cytotoxicity. Tamoxifen and other SERMs bind to cannabinoid receptors with moderate affinity. Therefore, ER-independent effects of SERMs might be mediated via cannabinoid receptors. This study determined whether RID-B, a first generation ridaifen compound, exhibits affinity and/or activity at CB

Indexed as

Adenylyl Cyclase InhibitorsAnimalsAnti-Inflammatory Agents, Non-SteroidalBenzoxazinesBinding, CompetitiveBone Marrow CellsCell DifferentiationCHO CellsCricetinaeCricetulusDrug Inverse AgonismMiceMice, Inbred C57BLMorpholinesNaphthalenesOsteoclasts(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanoneAdenylyl Cyclase InhibitorsAnti-Inflammatory Agents, Non-SteroidalBenzoxazinesMorpholinesNaphthalenesPyrrolidinesReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2ridaifen-BSelective Estrogen Receptor ModulatorsTamoxifenAntagonistCannabinoid receptorsDrug actionG-protein coupled receptorsInverse agonist

Identifiers

PMID29906493
PMCPMC6487498
OpenAlexW2807737798

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.